Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and ProQR (PRQR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report) and ProQR (PRQR – Research Report) with bullish sentiments.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Avadel Pharmaceuticals (AVDL)
In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Avadel Pharmaceuticals, with a price target of $22.00. The company’s shares closed last Friday at $7.99.
According to TipRanks.com, Brisebois is a 1-star analyst with an average return of
Avadel Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $19.14, which is a 137.5% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $19.00 price target.
See the top stocks recommended by analysts >>
ProQR (PRQR)
In a report released today, Andreas Argyrides from Oppenheimer initiated coverage with a Buy rating on ProQR and a price target of $15.00. The company’s shares closed last Friday at $2.56.
According to TipRanks.com, Argyrides is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $10.20 average price target.
Read More on AVDL:
- Oppenheimer cuts Avadel target, would buy on weakness
- Avadel Pharmaceuticals price target lowered to $17 from $23 at Craig-Hallum
- Piper Sandler cuts Avadel Pharmaceuticals price target, says staying bullish
- Avadel Pharmaceuticals price target lowered to $21 from $25 at H.C. Wainwright
- Avadel Pharmaceuticals price target lowered to $19 from $22 at Needham
